Arbutus Biopharma Corp (ABUS)
↓ Download CSV- Sector Manufacturing
- Incorporated A1
- Fiscal year ends Dec 31
In fiscal 2025, Arbutus Biopharma Corp reported revenue of $14.08M, up 128.2% from the prior year. The company ran a net loss, with a net margin of -237.9%. It held $94.62M in total assets against $18.04M in total liabilities.
Key ratios (FY2025)
-271.0%
Operating margin
-237.9%
Net margin
-43.7%
Return on equity
+128.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.08M | $6.17M | $18.14M | $39.02M | $10.99M | $6.91M | $6.01M | $5.95M | $10.70M | $1.49M |
| Operating Income | -$38.16M | -$76.32M | -$78.10M | -$65.46M | -$73.52M | -$57.81M | -$143.90M | -$89.78M | -$110.93M | -$491.64M |
| Net Income | -$33.50M | -$69.92M | -$72.85M | -$69.46M | -$76.25M | -$63.74M | -$153.72M | -$57.06M | -$84.41M | -$384.16M |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | — | $-1.21 | $-1.56 | $-7.24 |
| Total Assets | $94.62M | $131.71M | $144.40M | $195.42M | $204.49M | $137.08M | $105.53M | $227.91M | $237.16M | $275.92M |
| Total Liabilities | $18.04M | $34.34M | $38.38M | $58.57M | $35.05M | $35.11M | $32.79M | $27.67M | $54.69M | $72.91M |
| Shareholders' Equity | $76.58M | $97.37M | $106.02M | $136.85M | $169.44M | $101.97M | $72.74M | $200.23M | $182.47M | $203.00M |
| Cash & Equivalents | $18.01M | $36.33M | $26.29M | $30.78M | $109.28M | $52.25M | $31.80M | $36.94M | $54.29M | $23.41M |
| Operating Cash Flow | -$39.64M | -$64.85M | -$85.94M | -$35.36M | -$67.53M | -$51.44M | -$71.01M | -$67.87M | -$48.64M | -$57.88M |
| Capital Expenditures | $0 | $182.0K | $1.01M | $512.0K | $809.0K | $229.0K | $589.0K | $1.14M | $7.26M | $4.00M |
| Shares Outstanding | 192.53M | 189.96M | 169.87M | 157.46M | 144.99M | 89.68M | 64.78M | 55.52M | 55.06M | 54.84M |